LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

Search

Day One Biopharmaceuticals Inc

Fermé

SecteurSoins de santé

6.35 -2.46

Résumé

Variation du prix de l'action

24h

Actuel

Min

6.07

Max

6.52

Chiffres clés

By Trading Economics

Revenu

30M

-36M

Ventes

1.6M

31M

BPA

-0.35

Marge bénéficiaire

-117.018

Employés

181

EBITDA

24M

-40M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+350.3% upside

Dividendes

By Dow Jones

Prochains Résultats

29 juil. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-137M

667M

Ouverture précédente

8.81

Clôture précédente

6.35

Sentiment de l'Actualité

By Acuity

50%

50%

209 / 382 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Day One Biopharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

13 mai 2025, 23:20 UTC

Résultats

Aristocrat Leisure Boosts Half-Year Dividend, Keeps Focus on M&A

13 mai 2025, 23:48 UTC

Market Talk

Gold Edges Higher, Supported by Signs of Mild U.S. Inflation -- Market Talk

13 mai 2025, 23:43 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13 mai 2025, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for Improving U.S.-China Trade Relations -- Market Talk

13 mai 2025, 23:24 UTC

Market Talk
Résultats

Global Equities Roundup: Market Talk

13 mai 2025, 23:24 UTC

Market Talk
Résultats

Aristocrat's 1H Result Falls Short, Jefferies Says -- Market Talk

13 mai 2025, 22:58 UTC

Résultats

Table: Samsung Fire & Marine 1Q Consolidated Net KRW609.03B Vs KRW701.95B

13 mai 2025, 22:58 UTC

Résultats

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Net KRW609.03B Vs KRW701.95B

13 mai 2025, 22:58 UTC

Résultats

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Op Pft KRW792.36B Vs Op KRW897.06B

13 mai 2025, 22:58 UTC

Résultats

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Rev KRW6.106T Vs KRW5.507T

13 mai 2025, 22:38 UTC

Résultats

Aristocrat: Continues to Actively Pursue Strategic M&A Activities

13 mai 2025, 22:38 UTC

Résultats

Aristocrat: Remains Committed to Capital Management Strategy, Ongoing Share Buy-Back Program

13 mai 2025, 22:37 UTC

Résultats

Aristocrat: Expects More Operating Momentum in 2H Amid Product Rollout, Technology Initiatives

13 mai 2025, 22:36 UTC

Résultats

Aristocrat: Sees Accelerating Performance at Interactive Unit Toward FY 2029 US$1 Bln Revenue Target

13 mai 2025, 22:35 UTC

Résultats

Aristocrat: Expects Continued Market Share Gains from Gaming Unit

13 mai 2025, 22:34 UTC

Résultats

Aristocrat: Expects to Deliver NPATA Growth Over the Full Year on a Constant Currency Basis

13 mai 2025, 22:33 UTC

Résultats

Aristocrat: Interactive Business Delivered Strong Revenue Growth

13 mai 2025, 22:33 UTC

Résultats

Aristocrat: Gaming Unit Continued to Deliver Market Share Gains

13 mai 2025, 22:33 UTC

Résultats

Aristocrat: Product Madness' Key Social Casino Franchises Continued to Outperform

13 mai 2025, 22:30 UTC

Résultats

Aristocrat Interim Dividend 44 Australian Cents/Share

13 mai 2025, 22:30 UTC

Résultats

Aristocrat 1H Statutory Net Profit from Continuing Operations A$511 Mln, Down 21.6%

13 mai 2025, 22:29 UTC

Résultats

Aristocrat 1H Normalized Operating Revenue A$3 Bln, Up 8.7%

13 mai 2025, 22:28 UTC

Résultats

Aristocrat 1H Normalized Net Profit A$733 Mln, Up 5.6%

13 mai 2025, 21:15 UTC

Résultats

Nu Holdings 1Q Rev $3.2B >NU

13 mai 2025, 21:03 UTC

Actualités

GOP Mega Bill's Details Are Out. Now the Fighting Begins. -- WSJ

13 mai 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

13 mai 2025, 20:32 UTC

Résultats

Alcon Raises 2025 View To Sales $10.4B-$10.5B >ALC.EB

13 mai 2025, 20:31 UTC

Résultats

Alcon 1Q Sales $2.45B >ALC.EB

13 mai 2025, 20:30 UTC

Résultats

Alcon 1Q Rev $2.47B >ALC.EB

13 mai 2025, 20:30 UTC

Résultats

Alcon 1Q EPS 70c >ALC.EB

Comparaison

Variation de prix

Day One Biopharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

350.3% hausse

Prévisions sur 12 Mois

Moyen 29.63 USD  350.3%

Haut 40 USD

Bas 20 USD

Basé sur 9 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

9 ratings

8

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

6.26 / 7.47Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Bullish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

209 / 382Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Moyen

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.